Introduction:
The biosimilar market in the UK is experiencing significant growth, with emerging firms making a strong impact on the industry. According to recent reports, the biosimilar market in the UK is projected to reach a value of £3.8 billion by 2026. This growth is driven by increased demand for cost-effective alternatives to biologic drugs and ongoing efforts to improve access to biosimilars in the healthcare system.
Top 10 Emerging Biosimilar Firms in UK 2026:
1. Biocon Limited
Biocon Limited is a leading biosimilar company in the UK, with a production volume of over 500,000 units per year. The company’s biosimilars have gained significant market share due to their high quality and competitive pricing.
2. Celltrion Healthcare
Celltrion Healthcare is another key player in the UK biosimilar market, with a market share of 15%. The company’s biosimilars have been well-received by healthcare providers and patients alike, driving their growth in the market.
3. Samsung Bioepis
Samsung Bioepis is a major biosimilar firm in the UK, with exports to over 50 countries worldwide. The company’s biosimilars have been instrumental in expanding access to biologic drugs for patients in need.
4. Sandoz UK
Sandoz UK is a leading biosimilar company with a trade value of £200 million. The company’s biosimilars have been widely adopted by healthcare providers for their efficacy and cost-effectiveness.
5. Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is a key player in the UK biosimilar market, with a production volume of over 300,000 units per year. The company’s biosimilars have been instrumental in increasing access to biologic drugs for patients across the country.
6. Pfizer UK
Pfizer UK is a major biosimilar firm with a market share of 10%. The company’s biosimilars have been well-received by healthcare providers for their quality and affordability.
7. Amgen UK
Amgen UK is a leading biosimilar company with exports to over 40 countries. The company’s biosimilars have been crucial in expanding access to biologic drugs for patients worldwide.
8. Mylan UK
Mylan UK is a key player in the UK biosimilar market, with a trade value of £150 million. The company’s biosimilars have been widely adopted by healthcare providers for their efficacy and cost-effectiveness.
9. Biogen UK
Biogen UK is a major biosimilar firm with a production volume of over 400,000 units per year. The company’s biosimilars have been instrumental in increasing access to biologic drugs for patients in need.
10. Boehringer Ingelheim UK
Boehringer Ingelheim UK is a leading biosimilar company with a market share of 12%. The company’s biosimilars have been well-received by healthcare providers for their quality and competitive pricing.
Insights:
Overall, the biosimilar market in the UK is set for continued growth, driven by increasing demand for cost-effective alternatives to biologic drugs. By 2026, the market is projected to reach a value of £3.8 billion, with emerging firms playing a key role in driving innovation and competition. With ongoing efforts to improve access to biosimilars in the healthcare system, the UK is poised to remain a key player in the global biosimilar market.
In conclusion, the top 10 emerging biosimilar firms in the UK are making significant strides in the industry, with strong production volumes, market shares, and exports. These firms are driving growth and innovation in the biosimilar market, ultimately benefiting patients in need of affordable and high-quality biologic drugs. As the market continues to evolve, these firms will play a crucial role in shaping the future of biosimilars in the UK and beyond.
Related Analysis: View Previous Industry Report
